BnR Summit 2025

Belt and Road Summit 2025- Deal-making

10 – 16 Sept 2025 | China (Hong Kong)

Serilink Biotechnology Company Limited

www.serilinkhk.com/Hong Kong, China (Hong Kong)
6 profile visits

About

Serilink Biotechnology Company Limited (“Serilink”) specializes in peptide/protein drug synthesis, modification, and bioconjugations using novel technologies (OPA LinkTech). ​

​Its primary focus is on the development of antibody/peptide drug conjugates (ADCs, PDCs, collectively referred to as XDCs) and glycoconjugate vaccines. Serilink collaborates with partners to co-develop drugs, aiming at advancing them to the PCC or further to IND stage.​

We develop structurally innovative and performance-enhanced conjugated drug candidate compounds,empowering pharmaceutical companies in need of transformation and innovation, and providing new drug molecules and platform development technologies.

Technology

Bio-TechHealth TechnologyMedical Technology

Additional questions

Other Place of Business

Hong KongMainland China

Representatives

Hoi Yee Chow

COO

Serilink Biotechnology Company Limited

Marketplace (2)

  • Project

    Conjugated drug development platform

    Serilink is a company for conjugated drug development with a focus on ADCs, PDCs and RDCs.

    • No
    • Bio-Tech
    • Technology
    • IP Related
    • Consultancy
    • Joint Venture
    • Private Project
    • R&D Cooperation
    • Project Planning
    • Health Technology
    • Seed & Pre-Series
    • Medical Technology
    • Financial Services
    • Business Valuation
    • Open for Negotiation
    • Open for negotiation
    • Professional Services
    • 5,000,001 to 7,500,000 USD
    • 1,000,001 to 2,500,000 USD
    • Private Equity & Venture Capital
    Author

    Hoi Yee Chow

    COO at Serilink Biotechnology Company Limited

    Hong Kong, China (Hong Kong)

  • Project

    Q-Velox Fully Automated PCR Diagnostic System

    Q-Velox is a fully automated, real-time PCR based molecular diagnostic system with all-in-one disposable cartridge.

    • No
    • Equity
    • Series B
    • Bio-Tech
    • Operations
    • Technology
    • Joint Venture
    • Private Project
    • R&D Cooperation
    • Health Technology
    • Medical Technology
    • Financial Services
    • Financial Advisory
    • Open for Negotiation
    • Open for negotiation
    • Professional Services
    • Mergers & Acquisition
    • Minority Shareholdings
    • 500,001 to 1,000,000 USD
    • Institutional Investment
    • 25,000,001 to 50,000,000 USD
    • Market Entry Strategic Analysis
    • Private Equity & Venture Capital
    • Public–private partnership / Concession
    Author

    Hoi Yee Chow

    COO at Serilink Biotechnology Company Limited

    Hong Kong, China (Hong Kong)